From: Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis
Characteristic | HR (95% CI) | p value |
---|---|---|
Agea | 1.02 (0.96–1.08) | 0.493 |
ECOG performance statusa | 2.52 (1.25–5.09) | 0.010 |
Family History of Breast or Ovarian Cancer | ||
No | 1 | 0.593 |
Yes | 0.73 (0.23–2.30) | |
Histology | ||
HGCS | 1 | 0.747 |
Other histologies | 0.81 (0.22–3.00) | |
Time-point of CNS metastasis | ||
Platinum sensitive | 1 | 0.049 |
Platinum resistant | 2.89 (1.01–8.31) | |
Previous lines before diagnosis of BMa | 1.57 (1.12–2.19) | 0.008 |
Disease progression outside CNS | ||
No | 1 | 0.236 |
Yes | 0.52 (0.18–1.53) | |
Number of metastasisa | 1.06 (0.99–1.13) | 0.104 |
Metastasis sizea | 0.83 (0.49–1.39) | 0.473 |
Time from diagnosisa | 1.01 (1.00–1.01) | 0.200 |
Platinum free intervala | 0.99 (0.93–1.05) | 0.747 |